Thu, Jul 10, 2014, 10:54 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • blackmenrock@ymail.com blackmenrock Jun 6, 2012 3:26 PM Flag

    more good news coming?

    Takeda submitted to the EMA one year ago in June. That's about the normal wait for approval in Europe, so I'm guessing we will here some news within days rather than months. News on the UK filing is also pending. Both mean royalties + milestone payments B4 the end of the year. Canada is quicker and will most likely come before years end as well. SGEN gets 100% of Canadian sales and at least 10% ex-US for Europe.
    European sales of expensive cancer drugs has suffered do to austerity measures. Any drug that can only offer a few months and costs 100k is generally rejected by payers and replaced with an end of life discussion and hospice. Better to spend $2500 than $100k in their opinion.
    Adcetris' remarkable effeacy, especially in ALCL and HL, and the possibility for retreatment which can extend life indefinitely should allow it to overcome European cost concerns.
    Just another worthless opinion

 
SGEN
36.33+0.59(+1.65%)Jul 10 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.